All In Biotech

Drug Trial Radar · NCT07516951

A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab),in Participants With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jul 8, 2026

Primary completion

Jun 27, 2028

Study completion Jun 27, 2028

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Apr 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • CHF10067Drug

    Dose 1 CHF10067 Intravenous (IV) infusion

  • CHF10067Drug

    Dose 2 CHF10067 IV infusion

  • PlaceboOther

    Placebo IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome Measure: Absolute change from baseline in ppFVC (percent predicted forced vital capacity) at Week 24.Time frame: At Week 24

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research LLC

    Dothan, Alabama · Recruiting

  • Pasadena Center for Medical Research, Inc

    St. Petersburg, Florida · Recruiting

  • Hannibal Regional Healthcare System, Inc.

    Hannibal, Missouri · Recruiting

  • Clinical Research of Rock Hill

    Rock Hill, South Carolina · Recruiting

  • Tennessee Comprehensive Lung and Sleep Center

    Hendersonville, Tennessee · Recruiting

  • Premier Pulmonary Critical Care and Sleep Medicine, PA

    Denison, Texas · Recruiting

  • PHI University Clinic of Pulmonology and Allergology

    Skopje, North Macedonia · Recruiting

  • Soon Chun Hyang University Bucheon Hospital

    Bucheon-si, South Korea · Recruiting

  • Inje University Busan Paik Hospital

    Busan, South Korea · Recruiting

  • Inje University Haeundae Paik Hospital

    Busan, South Korea · Recruiting

  • Chonnam National University Hospital

    Gwangju, South Korea · Recruiting

  • Kyung Hee University Hospital

    Seoul, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Seoul Metropolitan Government-Seoul National University Boramae Medical Center

    Seoul, South Korea · Recruiting

  • Ajou University Hospital

    Suwon, South Korea · Recruiting

  • Royal Papworth Hospital NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • Royal Devon and Exeter Hospital - Royal Devon University Healthcare NHS Foundation Trust

    Exeter, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.